

# ANTI-CD40L mAb TREATMENT OF DONOR T CELLS IN A PRIMARY MLR CULTURE




FIG. 1

THE ADDITION OF ANTI-CD40L mAb INHIBITS IL-2 PRODUCTION IN PRIMARY MLR CULTURE




FIG. 2A

FIG. 2B

THE ADDITION OF ANTI-CD40L mAb LEADS TO A REDUCTION IN  
INTERFERON GAMMA PRODUCTION




FIG. 2B

# ANTI-CD40L mAb INDUCED ANTI-HOST ALLOANTIGEN HYPORESPONSIVENESS




FIG. 3A

DONOR T CELLS EXPOSED TO ANTI-CD40L mAb IN PRIMARY MLR CULTURE




FIG. 3B

THE ADDITION OF ANTI-CD40L mAb TO A PRIMARY MLR CULTURE INHIBITS IL-2 PRODUCTION




FIG. 4A

FIG. 4B

THE ADDITION OF ANTI-CD40L mAb TO A PRIMARY MLR CULTURE INHIBITS INTERFERON GAMMA PRODUCTION




FIG. 4B




FIG. 5A






FIG. 5B

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



## FILING COMPLETION UNDER RULE 53(f)

( NOT PCT Applications)  
For Design, Provisional, or Utility Applications

PATENT  
APPLICATION

**COMPLETION Under**  
Rule 53(f)

In re PATENT APPLICATION of

Inventor(s): Randolph J. NOELLE et al

Attn: Application Division

Appln. No.: 09 835,126  
Series Code ↑ Serial No. ↑

Atty. Dkt. P 0280602 1999-30-0522C1  
M# Client Ref

Filed: April 16, 2001

Title: EX VIVO TREATMENT OF ALLOGENIC AND XENOGENIC DONOR T-CELLS CONTAINING  
COMPOSITIONS (BONE MARROW) USING Gp39 ANTAGONISTS AND USES THEREOF

Hon. Commissioner of Patents  
Washington, DC 20231

Date: November 13, 2001

Sir:

The following completes the filing under Rule 53(f) of the above-identified patent application:

**Notice to File Missing Parts** ☐ copy attached ☐ not yet received

☐ Signed Declaration attached. ☐ Original ☐ Facsimile/Copy

(Always "X" box 2 if filing signed Declaration and

"X" box 2A only if top box of the Declaration is X'd and file application copy, or"X" box 2B only if none of the top three boxes of the Declaration is X'd.)

2A. ☐ Attached: Original signed Declaration with attached specification (including claim(s)) which is a copy of specification and claim(s) originally filed to secure the above filing date.

2B. ☐ The original application as filed in the PTO on the above filing date is the application which each inventor executed by signing the attached Rule 63 Declaration.

3. ☐ Specification originally filed in non-English language; hence verified translation attached of:

a. ☐ Abstractb. #  pages of Specification (only spec. & claims)c. ☐ Drawing(s)

No of Sheets

☐ Fig(s).

4. ☒ Letter filing formal drawing attached.

5. ☐ Attached is an assignment and cover sheet. Please return the recorded assignment to the undersigned.

6. DOMESTIC/INTERNATIONAL priority is claimed under 35 USC 119(e)/120/365(c) based on the following provisional, nonprovisional and/or PCT international application(s):

Application No.	Filing Date	Application No.	Filing Date
(1) 09/124,683	30 JULY 1998	(2)	
(3)		(4)	
(5)		(6)	

7. FOREIGN priority is claimed under 35 USC 119(a)-(d)/365(b) based on filing in \_\_\_\_\_

Application No.	Filing Date	Application No.	Filing Date
(1)		(2)	
(3)		(4)	
(5)		(6)	

Completion Under Rule 53(f)

9. \_\_\_\_\_ (No.) Certified copy (copies): ☐ attached; ☐ previously filed (date) \_\_\_\_\_  
in U.S. Application No. \_\_\_\_\_ / filed on \_\_\_\_\_
10. Small Entity Status ☐ ☒ is Not claimed ☐ is claimed (file PAT-256 if this is the first claim of Small Entity Status)
11. ☐ Attached:
12. ☐ Preliminary Amendment:

**THE FOLLOWING FILING FEE IS BASED ON CLAIMS AS FILED LESS ANY ABOVE CANCELLED**

				Large/Small Entity		Fee Code	
13. Basic Filing Fee .....				Design Application Not Design Application	\$320/\$160 \$710/\$355	+0	106/26 101/201
14. Total Effective Claims		minus 20 =		x \$18/\$9	+0	103/203	
15. Independent Claims		minus 3 =		x \$80/\$40	+0	102/202	
16. If <u>any proper</u> multiple dependent claim (ignore improper) is present, (Leave this line blank if this is a reissue application)				\$270/\$135	+0	104/204	
17. Surcharge for filing Declaration/filing fee late				\$130/\$65	+0	105/205	
18. <b>FILING FEE ENCLOSED =</b>				<b>0</b>			
19. <b>Original due date:</b> November 11, 2001*							
20. <b>Petition is hereby made</b> to extend the original due date to				(1 mo)	\$110/\$55 =	+0	115/215
cover the date this response is filed for which the requisite fee				(2mos)	\$390/\$195 =		116/216
is attached				(3mos)	\$890/\$445 =		117/217
				(4mos)	\$1390/\$695 =		118/218
21. If "non-English" box 3 is X'd, add Rule 17(k) processing fee .....				\$130	+0	139	
22. If "assignment" box 5 is X'd, add recording fee .....				\$40	+0	581	
23. Petition Fee for				\$130	+0		
24. *-Due to USPTO being closed on Nov. 12, 2001 because of National Holiday, document are being filed on Nov. 13, 2001.				<b>TOTAL FEE ENCLOSED =</b>	<b>\$0</b>		

Our Deposit Account No. 03-3975

Our Order No. 037003

0280602

C#

M#

**CHARGE STATEMENT:** The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official document under Rule 20, or credit any overpayment, to our Account/Order Nos. shown in the heading hereof for which purpose a duplicate copy of this sheet is attached. This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal form is filed.

**Pillsbury Winthrop LLP**  
**Intellectual Property Group**

1600 Tysons Boulevard

By Atty: Bonnie Weiss McLeodReg. No. 43,255

McLean, VA 22102

Sig: Bonnie W. McLeodFax: (703) 905-2500

Tel: (703) 905-2000

Tel: (703) 905-2219

Atty/Sec: BWM/ngm

**NOTE: File in duplicate with PTO receipt (PAT-103A) and attachments**